IQVIA Holdings (IQV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Rhyee from TD Cowen maintained a Buy rating on the stock and has a $175.00 price target.
Charles Rhyee has given his Buy rating due to a combination of factors that highlight IQVIA Holdings’ strengths despite anticipated challenges. While the RDS segment is expected to face headwinds from shifts in FSP and slower R&D growth among major pharmaceutical companies, IQVIA’s diversified earnings structure offers resilience. Notably, 45% of its earnings come from the TAS segment, which is experiencing a resurgence in demand and contributing positively to margins.
Rhyee’s analysis also considers the updated expectations for the CRO market and currency fluctuations. Although the RDS revenue projections for 2025 are slightly below management’s guidance, the TAS segment is projected to exceed expectations, driven by favorable foreign exchange changes and consistent growth. This balance between segments positions IQVIA to navigate macroeconomic challenges effectively, justifying the Buy rating despite potential setbacks in the RDS business.
In another report released on April 10, Truist Financial also maintained a Buy rating on the stock with a $216.00 price target.